On June 10, 2026, Beren Therapeutics P.B.C., a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, announced it has secured $300 million in combined financing. The financing consists of:

• $135 million equity financing round;
• Up to $110 million senior-secured debt facility with Hercules Capital, Inc.; and
• Up to $55 million of royalty financing with Hercules Capital, Inc.

The capital will support Beren’s growth strategies, including the potential U.S. commercial launch for adrabetadex to treat I-NPC and investments in patient access infrastructure and family support resources.

Wilson Sonsini Goodrich & Rosati advised Beren on each of the transactions. The Wilson Sonsini team that advised Beren on the transactions included: 

Corporate
Michael Coke
Travis Scheft
Sean Mihaljevich
Jacob Morales
Joseph Auer

Corporate Finance
Kathleen Rothman
Charles Gelinas
Jill Fulwiler
Eaton Liu

Technology Transactions
Miranda Biven
Norm Hovijitra
Colin Bosch
Kexi Wang

Tax
Myra Sutanto Shen
Gregory Broome
Robert Sherrill

Regulatory
Joshua Gruenspecht
Waqas Shahid 

Delaware
Ryan Greecher

For more information, please see Beren Therapeutics’ news release.